PHF5A promotes colorectal cancerprogression by alternative splicing of TEAD2

Dysregulated alternative splicing (AS) plays critical roles in driving cancer progression, and the underlying mechanisms remain largely unknown. Here, we demonstrated that PHF5A, a component of U2 small nuclear ribonucleoproteins, was frequently upregulated in colorectal cancer (CRC) samples and ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Yue, Zhao, Yulu, Wang, Liya, Wu, Meijuan, He, Chenglong, Huang, Mengxi, Lei, Zengjie, Yang, Jiahe, Han, Siqi, Wang, Bibo, Chen, Yanyan, Liu, Chao, Yu, Hongju, Xue, Lijun, Geng, Jian, Chen, Yanan, Dai, Tingting, Ren, Lili, Wang, Qian, Liu, Xiaobei, Chu, Xiaoyuan, Chen, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605294/
https://www.ncbi.nlm.nih.gov/pubmed/34853721
http://dx.doi.org/10.1016/j.omtn.2021.10.025
Descripción
Sumario:Dysregulated alternative splicing (AS) plays critical roles in driving cancer progression, and the underlying mechanisms remain largely unknown. Here, we demonstrated that PHF5A, a component of U2 small nuclear ribonucleoproteins, was frequently upregulated in colorectal cancer (CRC) samples and associated with poor prognosis. PHF5A promoted proliferation and metastasis of CRC cells in vitro and in vivo. Transcriptomic analysis identified PHF5A-regulated AS targets and pathways. Particularly, PHF5A induced TEAD2 exon 2 inclusion to activate YAP signaling, and interference of TEAD2-L partially reversed the PHF5A-mediated tumor progression. Pharmacological inhibition of PHF5A using pladienolide B had potent antitumor activity. Collectively, these data revealed the oncogenic role of PHF5A in CRC through regulating AS and established PHF5A as potential therapeutic target.

Ejemplares similares